Accordingly, we wonder whether inhibition of the CD95 dimer/trimer in patients treated with CAR-T cells could represent a therapeutic approach to prevent the “precocious differentiation” of TSCM and increase the anti-tumor response by CAR-T cells. Here, FAS is linked to neoplasm.